Last updated: August 2, 2026
Amphastar Pharmaceuticals is a specialty pharmaceutical company built around complex generic drugs, injectable products, intranasal delivery systems and selected branded medicines. Its strongest competitive positions are in glucagon, epinephrine, naloxone, enoxaparin, corticosteroid products and hospital-use injectables. The acquisition of Baqsimi expanded Amphastar into branded emergency medicine and added a differentiated nasal delivery platform.
The company’s investment case depends on five factors: execution of complex products, limited generic competition in selected markets, manufacturing capacity, lifecycle management and pipeline conversion. Its principal risks are product concentration, pricing pressure, regulatory delays, patent challenges and competition from larger generic manufacturers.
What is Amphastar Pharmaceuticals’ market position?
Amphastar competes in markets where regulatory and manufacturing complexity can reduce the number of viable suppliers. The company is smaller than Teva, Viatris, Sandoz, Fresenius Kabi and Hikma, but it focuses on products that are harder to develop than conventional oral tablets.
Amphastar reported approximately $646 million in net revenue for 2023, compared with approximately $555 million in 2022. Growth reflected higher sales of core products, the contribution from Baqsimi and increased demand for selected injectable and emergency-care products. The company’s product portfolio is concentrated but has a higher proportion of complex products than a typical generic manufacturer (Amphastar Pharmaceuticals, 2024).
Amphastar’s principal commercial products
| Product |
Active ingredient |
Dosage form |
Market role |
Primary competitive issue |
| Baqsimi |
Glucagon |
Intranasal powder |
Branded emergency treatment for severe hypoglycemia |
Generic and alternative glucagon devices |
| Primatene Mist |
Epinephrine |
Metered-dose inhaler |
OTC treatment for mild intermittent asthma |
Consumer demand, OTC distribution and inhaler competition |
| Glucagon injection |
Glucagon |
Injectable kit or vial |
Emergency hypoglycemia treatment |
Multiple generic suppliers and newer delivery systems |
| Cortrosyn |
Cosyntropin |
Injectable diagnostic agent |
Adrenal function testing |
Hospital purchasing and supply continuity |
| Amphadase |
Hyaluronidase |
Injectable enzyme |
Facilitates subcutaneous fluid and drug absorption |
Institutional contracting and competing hyaluronidase products |
| Enoxaparin |
Enoxaparin sodium |
Prefilled syringe and injection |
Anticoagulant |
Price competition from generic manufacturers |
| Naloxone products |
Naloxone |
Injectable or nasal delivery |
Opioid overdose reversal |
Public-sector tenders and branded nasal products |
| Insulin and peptide pipeline products |
Various |
Injectable or other delivery systems |
Potential biosimilar or complex generic markets |
Clinical, device and manufacturing execution |
Amphastar is positioned between traditional generic manufacturers and specialty pharmaceutical companies. It uses generic approval pathways where available but develops proprietary formulations, devices and delivery systems to limit direct substitution.
How does Amphastar compare with major generic pharmaceutical competitors?
Amphastar has less scale than the largest generic manufacturers but operates in narrower markets with greater technical barriers.
| Company |
Core strength |
Relative position versus Amphastar |
| Teva Pharmaceutical Industries |
Global generic scale and complex generics |
Larger geographic reach and broader product portfolio |
| Viatris |
Global commercial infrastructure and branded-generics portfolio |
Greater scale, but more diversified and less focused on Amphastar’s niche products |
| Sandoz |
Biosimilars, injectables and global generics |
Stronger biosimilar platform and international presence |
| Fresenius Kabi |
Hospital injectables, infusion products and medical technologies |
Greater institutional scale and hospital-channel depth |
| Hikma Pharmaceuticals |
Injectables, generics and branded products |
Direct competitor in injectable and hospital markets |
| Pfizer |
Sterile injectables through legacy Hospira assets |
Greater manufacturing scale and hospital access |
| Emergent BioSolutions |
Naloxone and public-health products |
Direct competitor in overdose-reversal products |
| Novo Nordisk |
Diabetes and obesity medicines |
Greater scale in glucagon-adjacent diabetes markets |
| Eli Lilly |
Diabetes and branded medicines |
Former owner of Baqsimi and a major diabetes competitor |
| Sanofi |
Diabetes, specialty care and consumer health |
Larger branded and international commercial infrastructure |
Amphastar’s advantage is product selection. It does not need to match Teva or Viatris in volume if it can maintain attractive economics in products that require specialized analytical methods, sterile manufacturing, device integration or clinical bridging.
What products and technologies give Amphastar a competitive advantage?
Amphastar’s competitive advantages are concentrated in delivery systems and difficult-to-manufacture products.
Intranasal delivery
Baqsimi uses a dry nasal powder formulation of glucagon. The product eliminates the need for reconstitution and injection, which supports use by caregivers during severe hypoglycemia emergencies. Its commercial differentiation is based on ease of administration rather than a new active ingredient.
The intranasal platform also creates barriers involving powder engineering, moisture control, device performance, dose uniformity, stability and human-factor performance. A competing product must demonstrate equivalent drug delivery and device performance, not merely match the glucagon molecule.
Complex injectables
Amphastar develops products involving peptides, enzymes, anticoagulants and other injectable molecules. These products require sterile manufacturing, validated analytical methods, container-closure controls and consistent batch performance.
The main barrier is often execution rather than a single composition-of-matter patent. Regulatory approval can require extensive chemistry, manufacturing and controls documentation, comparative clinical data, device testing or a complex generic development package.
Peptide and insulin development
Amphastar has invested in insulin and peptide products, including products aimed at markets with substantial commercial demand. These programs may create a more durable growth platform than mature injectable generics, but they also require greater capital, clinical development and manufacturing investment.
The strategic value of the pipeline is highest where the reference product has large revenue, limited approved competitors or device-related barriers. Development risk rises when several global manufacturers are pursuing the same molecule.
What patents protect Amphastar products?
Amphastar’s patent protection is product-specific. The company does not rely on one broad patent estate covering its entire portfolio.
Baqsimi patent and exclusivity position
Baqsimi was developed by Eli Lilly and acquired by Amphastar in 2023. The relevant protection may include formulation, nasal powder, device, manufacturing and method-of-use claims. The FDA Orange Book identifies patents and regulatory exclusivity associated with approved products, but listing status and expiration dates can change through patent-term adjustment, litigation, delisting or regulatory updates (U.S. Food and Drug Administration, n.d.-a).
Baqsimi’s protection is stronger than that of a conventional injectable glucagon product because a substitute may need to address both formulation and delivery-device claims. The main generic entry route is an abbreviated application that demonstrates equivalence to the listed reference product and addresses each applicable patent through certification or a statement.
Primatene Mist patent position
Primatene Mist is an OTC epinephrine metered-dose inhaler approved by the FDA in 2018. Its commercial protection depends more on regulatory status, brand recognition, device and formulation execution than on a long period of new-molecule exclusivity. The active ingredient, epinephrine, is long established.
Potential competitive barriers include inhaler design, dose uniformity, propellant and formulation controls, OTC labeling and consumer distribution. A competitor would need to satisfy both pharmaceutical and consumer-product requirements.
Injectable and complex-generic products
For injectable products such as enoxaparin, hyaluronidase and cosyntropin, protection can involve:
- Formulation and concentration claims
- Stable pharmaceutical compositions
- Container-closure systems
- Manufacturing processes
- Device or prefilled-syringe configurations
- Methods of treating or diagnosing a defined condition
- Regulatory exclusivity associated with approval
Method-of-use patents generally have narrower commercial value than composition or formulation patents because they may be avoided through labeling or prescribing practices. Manufacturing patents can still be important when the process is difficult to replicate and the product cannot be economically produced through an alternative route.
When does Amphastar lose exclusivity?
Amphastar has no single company-wide exclusivity date. Each product has a separate combination of patents, FDA exclusivity, trademarks, manufacturing controls and commercial positioning.
| Product or platform |
Key protection type |
Expected strategic issue |
| Baqsimi |
Formulation, device, manufacturing and possible method claims |
Timing of ANDA or 505(b)(2) competition |
| Primatene Mist |
OTC approval, inhaler technology, brand and distribution |
Entry by other epinephrine inhalers |
| Enoxaparin |
Complex generic approval and formulation/process controls |
Price erosion from additional approved suppliers |
| Cortrosyn |
Injectable product approval, manufacturing and supply reliability |
Institutional substitution and contracting |
| Amphadase |
Injectable enzyme formulation and manufacturing |
Competition from hyaluronidase suppliers |
| Insulin pipeline |
Patent, regulatory, device and manufacturing protection |
Biosimilar and follow-on insulin competition |
Exact patent expiration dates must be evaluated from the current FDA Orange Book, United States Patent and Trademark Office records and litigation filings. FDA-listed patents do not always provide the full commercial protection period because patent-term adjustment, pediatric exclusivity, settlement agreements and court decisions can affect launch timing.
What is the Orange Book status of Amphastar products?
The Orange Book is most relevant to Amphastar’s approved prescription drugs and products approved under abbreviated or hybrid pathways. It identifies listed patents, exclusivity periods, reference products and therapeutic-equivalence information (U.S. Food and Drug Administration, n.d.-a).
Baqsimi is the most strategically important Orange Book product in the portfolio because it is a branded reference product acquired from Lilly. Orange Book-listed patents can create a certification burden for an ANDA applicant. A Paragraph IV certification may trigger patent litigation and a potential 30-month stay of approval under the Hatch-Waxman framework, subject to statutory requirements and court developments.
OTC products such as Primatene Mist require a different analysis. The commercial barrier may rely less on Orange Book patent listings and more on the regulatory pathway, device development, OTC labeling and manufacturing capability.
Which companies are challenging Amphastar products?
Competitive pressure comes from several groups rather than one identified challenger.
Generic glucagon manufacturers
Generic manufacturers can compete with injectable glucagon through ANDA approvals. These products may offer lower prices but do not necessarily substitute directly for Baqsimi because Baqsimi is administered intranasally and does not require reconstitution.
Nasal naloxone and emergency-care companies
Emergent competes in naloxone through Narcan and related products. The naloxone market is influenced by public procurement, OTC availability, government grants, opioid-response programs and retail distribution. Amphastar’s position depends on product format, price and access to institutional contracts.
Large injectable manufacturers
Hikma, Fresenius Kabi, Pfizer, Sandoz and other manufacturers compete in hospital injectables. These companies can exert pressure through purchasing contracts, portfolio bundling, supply reliability and international distribution.
Diabetes-focused companies
Novo Nordisk, Eli Lilly and Sanofi have much greater diabetes infrastructure and physician access. Amphastar’s opportunity is to enter selected products where regulatory or device barriers limit direct competition. Its disadvantage is lower scale in sales, clinical development and diabetes-market access.
What Paragraph IV challenges affect Amphastar?
A Paragraph IV challenge alleges that an Orange Book-listed patent is invalid, unenforceable or not infringed. It can accelerate litigation before generic entry and may produce a settlement that defines a future launch date.
For Amphastar, the principal Paragraph IV exposure is associated with products that have listed patents and meaningful generic-market value, particularly branded or complex products. Baqsimi is the most commercially significant asset for this analysis because a generic applicant could pursue an ANDA or another FDA pathway targeting the reference product.
The commercial impact depends on:
- The number and scope of listed patents.
- Whether the patents cover the active ingredient, formulation, device or manufacturing process.
- The strength of noninfringement and invalidity defenses.
- The date of any first-filer exclusivity.
- The availability of alternative glucagon products.
- The terms of any litigation settlement.
No broad conclusion that all Amphastar products are insulated from Paragraph IV risk is supportable. Mature injectable products generally face higher price erosion risk, while device-linked products may have a longer period before direct substitution.
How strong is Amphastar’s patent estate?
Amphastar’s patent estate is strongest where patents are combined with regulatory and manufacturing barriers.
| Patent category |
Relative strength for Amphastar |
Reason |
| New chemical entity patents |
Low to moderate |
Most products use established active ingredients |
| Formulation patents |
Moderate to strong |
Can limit equivalent delivery and stability approaches |
| Device patents |
Moderate to strong |
Relevant to nasal, inhaled and prefilled products |
| Manufacturing patents |
Moderate |
Valuable when alternative processes are difficult |
| Method-of-use patents |
Moderate to weak |
Narrower scope and possible label-avoidance strategies |
| Trade secrets and know-how |
Strong operational value |
Supports process consistency and scale |
| Regulatory exclusivity |
Product-dependent |
Time-limited but may delay approval |
| Trademark and brand equity |
Strong for select products |
Important for OTC and emergency products |
The company’s defensibility is therefore hybrid. Patent claims matter, but they work with formulation know-how, sterile production, device integration, regulatory experience and distribution.
What manufacturing and intellectual-property barriers protect Amphastar?
Manufacturing is a significant barrier in injectable and complex products. Amphastar’s manufacturing network supports development and commercial supply of sterile products, nasal powders, inhaled products and other dosage forms.
Key barriers include:
- Sterile fill-finish capacity
- Aseptic process validation
- Peptide and protein characterization
- Nasal powder engineering
- Device assembly and quality controls
- Cold-chain and stability management
- Complex analytical comparability
- Scale-up from development to commercial batches
- FDA inspection readiness
These barriers can delay competitors even when patent protection is limited. They also create operational risk. A manufacturing deviation, warning letter, supply interruption or product recall can reduce revenue quickly because several products may depend on a limited number of facilities.
What FDA regulatory milestones matter for Amphastar?
| Year |
Regulatory or commercial milestone |
| 2018 |
FDA approved Primatene Mist as an OTC epinephrine inhaler |
| 2019 |
Primatene Mist commercial launch |
| 2019 |
FDA approved Baqsimi, developed by Eli Lilly, as the first ready-to-use nasal glucagon product |
| 2020-2022 |
Amphastar expanded its complex injectable and generic product portfolio |
| 2023 |
Amphastar acquired Baqsimi from Eli Lilly |
| 2023 onward |
Baqsimi became a branded growth asset within Amphastar’s portfolio |
FDA approval alone does not determine commercial success. Product supply, payer coverage, retail access, prescriber awareness and patient or caregiver usability drive the revenue outcome.
What licensing deals and acquisitions affect Amphastar?
The Baqsimi transaction with Eli Lilly is Amphastar’s most important recent business-development deal. It transferred commercial rights and related assets for the nasal glucagon product to Amphastar, giving the company a branded emergency medicine with a differentiated delivery system.
The transaction also changed Amphastar’s risk profile. Before the acquisition, the company was more heavily associated with generic and specialty injectable products. After the acquisition, it gained:
- A branded diabetes product
- A direct-to-consumer and retail opportunity
- A nasal delivery platform
- Greater exposure to glucagon market growth
- Higher commercial and lifecycle-management responsibilities
The acquisition creates integration risk because Amphastar must maintain supply, market the product and defend or manage the associated intellectual property.
What generic launch scenarios exist for Amphastar products?
Scenario 1: Delayed direct competition
Baqsimi could maintain a period of branded pricing and market share if patent, device or formulation barriers delay an equivalent generic. Amphastar could extend the product’s commercial life through additional presentations, geographic expansion or lifecycle improvements.
Scenario 2: First generic entry
A first generic glucagon nasal product could trigger a sharp price reduction, although the impact would depend on pharmacy substitution, payer policies and whether the generic matches the device and user experience.
Scenario 3: Multiple generic launches
Mature injectable products such as enoxaparin and glucagon injection are more exposed to rapid price erosion when several suppliers enter. Hospital contracting can accelerate volume shifts.
Scenario 4: Non-equivalent competitive substitution
A competing injectable, autoinjector or nasal product may not be an Orange Book-equivalent generic but could still reduce demand through clinical preference, payer policy or public procurement.
What geographic markets does Amphastar cover?
Amphastar’s commercial base is primarily the United States. The U.S. market provides higher pricing and a more developed framework for complex generics, branded emergency products and Orange Book litigation.
International expansion is more limited than for Teva, Viatris, Sandoz, Hikma and Fresenius Kabi. This limits administrative complexity and foreign-market exposure, but it also reduces the company’s ability to offset U.S. price erosion with overseas growth.
Geographic expansion opportunities exist in:
- Canada
- Europe
- Australia
- Selected Latin American markets
- Public-health and emergency-medicine procurement markets
Each market requires separate regulatory approval, patent analysis, reimbursement work and distribution arrangements. A U.S. approval does not create automatic market access elsewhere.
What revenue exposure and investment risks should investors monitor?
The most important financial variables are product concentration, Baqsimi growth, pipeline approvals, gross margin, manufacturing utilization and generic price erosion.
Positive drivers
- Growth in branded Baqsimi sales
- New approvals in complex generics
- Expansion of insulin and peptide programs
- Continued demand for emergency medicines
- Limited competition in specialized injectables
- Improved utilization of manufacturing assets
Negative drivers
- Additional approvals in mature injectable markets
- Baqsimi patent litigation or earlier generic entry
- Product recalls or manufacturing interruptions
- Clinical or regulatory failure in insulin programs
- Higher research and development spending
- Payer pressure on branded emergency medicines
- Dependence on U.S. sales
Amphastar’s earnings quality is stronger when growth comes from differentiated products and new approvals. It is weaker when revenue depends on temporary supply shortages or short-lived generic pricing.
How does Amphastar compare with comparable specialty pharmaceutical companies?
Amphastar has a more concentrated portfolio than diversified generic companies but a higher level of product specificity. Compared with Hikma, it has less international reach and a narrower hospital portfolio. Compared with Sandoz, it has less biosimilar scale. Compared with Emergent, it has a broader pharmaceutical portfolio but less concentration in public-health procurement. Compared with Novo Nordisk and Eli Lilly, it has substantially less diabetes infrastructure but can compete in targeted emergency products.
Its strategic position is strongest in markets where:
- The molecule is established but difficult to formulate.
- The dosage form requires specialized devices.
- Sterile manufacturing capacity is limited.
- Regulatory development requires complex analytical work.
- The product has a meaningful emergency or hospital-use function.
- Brand and distribution remain important after generic approval.
Key Takeaways
- Amphastar is a specialized U.S. pharmaceutical manufacturer focused on complex generics, injectables, emergency medicines and differentiated delivery systems.
- Its 2023 revenue was approximately $646 million, with Baqsimi adding an important branded growth asset.
- Baqsimi is the company’s most strategically significant product because nasal delivery creates formulation, device and regulatory barriers.
- The portfolio remains exposed to generic price erosion, especially in mature injectable markets.
- Amphastar’s patent protection is product-specific and strongest when formulation, device, manufacturing and regulatory barriers overlap.
- The company has less scale than Teva, Viatris, Sandoz, Hikma and Fresenius Kabi, but competes in narrower markets with higher technical complexity.
- Insulin and peptide programs could materially expand the addressable market but carry greater regulatory, clinical and manufacturing risk.
- Baqsimi patent litigation, FDA approvals, manufacturing capacity and product concentration are the main strategic variables.
FAQs About Amphastar Pharmaceuticals’ Competitive Landscape
Is Amphastar a generic drug company or a branded pharmaceutical company?
Amphastar is both. Its portfolio includes complex generic injectables and branded products such as Baqsimi and Primatene Mist. The company’s strategy combines generic approval pathways with proprietary formulations, devices and specialty-market products.
Does Amphastar compete with Novo Nordisk in glucagon?
Yes, but the competitive overlap is limited by product format and market segment. Novo Nordisk has broader diabetes scale, while Amphastar’s Baqsimi competes through ready-to-use intranasal delivery and emergency usability.
Is Baqsimi protected by patents after the Eli Lilly acquisition?
Baqsimi may be protected by patents covering its formulation, nasal delivery system, manufacturing process and methods of use. The current Orange Book listing and expiration dates determine the operative Hatch-Waxman framework.
Could a generic version of Baqsimi launch before all patents expire?
A generic applicant could challenge listed patents through a Paragraph IV certification. Entry could occur before patent expiration if the challenger prevails, reaches a settlement, licenses the product or launches after addressing the applicable patents.
What is Amphastar’s biggest long-term strategic risk?
The main long-term risk is failure to replace declining mature-product revenue with new complex generic, branded or peptide products. The company’s smaller scale increases the effect of regulatory delays, manufacturing problems and product concentration.
References
-
Amphastar Pharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
Eli Lilly and Company. (2019). Lilly receives FDA approval for Baqsimi, the first nasal glucagon for severe hypoglycemia. Company press release.
-
U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (n.d.-b). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2018). FDA approves first generic version of naloxone nasal spray. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2018). FDA approves Primatene Mist for over-the-counter use. U.S. Department of Health and Human Services.
